Helus Pharma Advances New Drug for Anxiety Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy HELP?
Source: Newsfilter
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HELP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HELP
Wall Street analysts forecast HELP stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.500
Low
22.00
Averages
41.17
High
55.00
Current: 5.500
Low
22.00
Averages
41.17
High
55.00
About HELP
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Helus Pharma Welcomes White House Executive Order on Psychedelic Treatments
- Policy Driving Innovation: The White House's new Executive Order aims to accelerate research and regulatory pathways for mental health treatments, reflecting the urgent need for new options, with Helus Pharma actively contributing to this progress through the development of its HLP003 program.
- Breakthrough Therapy Designation: Helus Pharma's HLP003 is currently in Phase 3 clinical development and has received Breakthrough Therapy designation from the FDA for adjunctive treatment of major depressive disorder, showcasing the company's strategic positioning to meet market demands.
- Funding Support and Coordination: The Executive Order includes increased federal funding to support state-level programs and strengthens coordination among the Department of Health and Human Services, FDA, and Department of Veterans Affairs, creating a favorable policy environment for Helus Pharma's innovative drug development.
- Significant Market Potential: Helus Pharma believes that with policy momentum and the accumulation of clinical evidence, more patients will benefit from novel mental health treatments, particularly where existing therapies are insufficient, positioning the company to fill this market gap.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
White House Psychedelics Executive Order Accelerates Research
- Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
- Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
- Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
- Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.
See More
Helus Pharma CEO Michael Colais Steps Down Immediately
- Executive Change: Helus Pharma announced that CEO Michael Colais has stepped down immediately at the request of the board, indicating a significant leadership shift that may impact investor confidence.
- Interim Leadership: Co-founder and executive chairman Eric So has been appointed as interim CEO to ensure continuity of leadership, helping the company maintain stability during the transition while searching for a new CEO.
- Successor Search: The board has initiated a search process for a permanent CEO, a move that could influence the company's strategic direction and future development, prompting investors to monitor subsequent developments closely.
- Market Reaction: Helus Pharma's stock rose 8.73% in pre-market trading to $5.98, reflecting market optimism regarding the new leadership and potential confidence in the company's future prospects.
See More
Helus Pharma Announces Transition in Leadership; Eric So to Take on Interim CEO Role
Leadership Change: Helus Pharma has announced a transition in its Chief Executive Officer position.
Interim Appointment: Eric Soto will assume the role of interim Chief Executive Officer during this transition period.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
Helus Pharma Welcomes White House Executive Order on Psychedelic Treatments
- Policy Driving Innovation: The White House's new Executive Order aims to accelerate research and regulatory pathways for mental health treatments, reflecting the urgent need for new options, with Helus Pharma actively contributing to this progress through the development of its HLP003 program.
- Breakthrough Therapy Designation: Helus Pharma's HLP003 is currently in Phase 3 clinical development and has received Breakthrough Therapy designation from the FDA for adjunctive treatment of major depressive disorder, showcasing the company's strategic positioning to meet market demands.
- Funding Support and Coordination: The Executive Order includes increased federal funding to support state-level programs and strengthens coordination among the Department of Health and Human Services, FDA, and Department of Veterans Affairs, creating a favorable policy environment for Helus Pharma's innovative drug development.
- Significant Market Potential: Helus Pharma believes that with policy momentum and the accumulation of clinical evidence, more patients will benefit from novel mental health treatments, particularly where existing therapies are insufficient, positioning the company to fill this market gap.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
White House Psychedelics Executive Order Accelerates Research
- Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
- Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
- Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
- Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.
See More
Helus Pharma CEO Michael Colais Steps Down Immediately
- Executive Change: Helus Pharma announced that CEO Michael Colais has stepped down immediately at the request of the board, indicating a significant leadership shift that may impact investor confidence.
- Interim Leadership: Co-founder and executive chairman Eric So has been appointed as interim CEO to ensure continuity of leadership, helping the company maintain stability during the transition while searching for a new CEO.
- Successor Search: The board has initiated a search process for a permanent CEO, a move that could influence the company's strategic direction and future development, prompting investors to monitor subsequent developments closely.
- Market Reaction: Helus Pharma's stock rose 8.73% in pre-market trading to $5.98, reflecting market optimism regarding the new leadership and potential confidence in the company's future prospects.
See More
Helus Pharma Announces Transition in Leadership; Eric So to Take on Interim CEO Role
Leadership Change: Helus Pharma has announced a transition in its Chief Executive Officer position.
Interim Appointment: Eric Soto will assume the role of interim Chief Executive Officer during this transition period.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
